It has been known as a fundamentally-oriented investment organization manager which has its aim at investments that have long-term value. It is none other than Kerrisdale Capital Management, LLC which is an active member of Financial Industry Regulatory Authority. It is headed and managed by Sahm Adrangi. He also happens to be the Founder and Chief Investment Officer of the same investment manager.
Mr. Sahm Adrangi founded Kerrisdale in 2009 and has taken the firm from one development to another and has been involved in various aspects of the firm. The private investment manager has been involved in publishing several negative reports expressing its short positions in certain market situations. Recently, it explained its thought on NASDAQ: the QNST stock of an internet marketing company called QuinStreet Inc. which has risen four times than it was. This has blinded the eyes of the investors who now think that the company is on the right track. Nevertheless, according to Sahm Adrangi of Kerrisdale, the sustainability of QuinStreet is from some fake web traffic. As the client clicks and fills their form, QuinStreet’s revenue increases at the expense of an innocent client.
Kerrisdale also expressed their short position in the stock NYSE:KODK which belongs to Eastman Kodak Company which is basically involved in imaging and printing. After an announcement that the company will have a platform in the blockchain technology, their stock has risen with 187%. Nevertheless, Sahm Adrangi argues that this is just an ICO craze chase which is meant to cover up the poor fundamentals and capital structures of Kodak Company but it will fail terribly.
Sahm Adrangi has also some negative report on the stock NASDAQ: PTI which belongs to Proteostasis Therapeutics, Inc. The company is a biopharmaceutical that is involved in development stages of drugs that treat cystic fibrosis and currently testing PTI-428 drug. After being granted Breakthrough Therapy and Orphan Drug of PTI-428 by FDA, its stock rose by almost 100%. However, Kerrisdale argues that the drug is ineffective and Proteostasis Therapeutics is not disclosing all the information to the public about the PTI-428 drug.
Mr. Sahm Adrangi has dealt with financial matters in his prior jobs like in Deutsche Bank, Longacre Fund Management, and Chanin Capital Partners. He studied at Yale University for BA.